4.3 Review

Recent developments in the pathobiology of lung myofibroblasts

Journal

EXPERT REVIEW OF RESPIRATORY MEDICINE
Volume 15, Issue 2, Pages 239-247

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/17476348.2021.1829972

Keywords

Lung fibrosis; myofibroblast; alpha-SMA; cellular metabolism; glycolysis; glutaminolysis; senescence; apoptosis; resolution

Funding

  1. NIH [HL135830]
  2. Department of Defense [W81XWH-20-1-0226]
  3. National Natural Science Foundation of China [81700067, 81870056]

Ask authors/readers for more resources

The latest studies have significantly advanced the understanding of the role and regulation of lung myofibroblasts in lung fibrosis, leading to the emergence of new therapeutic strategies.
Introduction: Myofibroblasts are the primary executor and influencer in lung fibrosis. Latest studies on lung myofibroblast pathobiology have significantly advanced the understanding of the pathogenesis of lung fibrosis and shed new light on strategies targeting these cells to treat this disease. Areas covered: This article reviewed the most recent progresses, mainly within the last 5 years, on the definition, origin, activity regulation, and targeting of lung myofibroblasts in lung fibrosis. We did a literature search on PubMed using the keywords below from the dates 2010 to 2020. Expert opinion: With the improved cell lineage characterization and the advent of scRNA-seq, the field is having much better picture of the lung myofibroblast origin and mesenchymal heterogeneity. Additionally, cellular metabolism has emerged as a key regulation of lung myofibroblast pathogenic phenotype and is a promising therapeutic target for treating a variety of lung fibrotic disorders.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available